X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TTHX1114 is an investigational engineered fibroblast growth factor-1, which stimulates cell proliferation and migration as well as protecting cells from stress and injury. The topical formulation of TTHX1114 is designed to accelerate corneal ulcer wound healing.
Lead Product(s): TTHX1114
Therapeutic Area: Ophthalmology Product Name: TTHX1114
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
The financing will support the development of its engineered FGF-1, TTHX1114 products for the regenerative treatment of corneal diseases. TTHX1114 has also shown in animal models a reduction in the severity of both chemical and herpes-induced corneal damage.
Lead Product(s): Engineered FGF-1
Therapeutic Area: Ophthalmology Product Name: TTHX1114
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Hatteras Venture Partners
Deal Size: $28.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 01, 2021
Details:
The “STORM” study, the second clinical trial of TTHX1114, is designed to assess its potential to enhance corneal recovery and improve visual acuity in FECD patients undergoing Descemetorhexis without Endothelial Keratoplasty (DWEK).
Lead Product(s): TTHX1114
Therapeutic Area: Ophthalmology Product Name: NM141
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2021
Details:
TTHX1114, administered by intracameral injection, is currently undergoing a Phase 1/2 clinical study to assess its safety and ability to regenerate corneal endothelial cells lost due to corneal endothelial dystrophies, including Fuchs endothelial corneal dystrophy.
Lead Product(s): TTHX1114
Therapeutic Area: Ophthalmology Product Name: NM141
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
The Phase 1/2 trial (“INTREPID”) is designed to evaluate TTHX1114’s safety and ability to stimulate the regeneration of corneal endothelial cells lost due to CED when administered by intracameral (back of the cornea) injection.
Lead Product(s): TTHX1114
Therapeutic Area: Ophthalmology Product Name: NM141
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2020
Details:
AGC Biologics will assist Trefoil Therapeutics with the production of their life changing product, TTHX1114, engineered form of FGF-1 to restore lost vision in patients with corneal diseases.
Lead Product(s): TTHX1114
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: AGC Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 04, 2020
Details:
Trefoil is developing products based on FGF-1 to restore lost vision in patients with corneal diseases by regenerating corneal tissue.
Lead Product(s): TTHX1114
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
